Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2025 | 818 | 5.890 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2025 | 197 | 3.810 |
Why?
|
| Methotrexate | 9 | 2025 | 355 | 3.690 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 63 | 3.280 |
Why?
|
| Cerebellar Neoplasms | 8 | 2024 | 461 | 2.700 |
Why?
|
| Medulloblastoma | 7 | 2024 | 571 | 2.450 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 216 | 2.020 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 66 | 1.630 |
Why?
|
| Metabolomics | 4 | 2025 | 471 | 1.530 |
Why?
|
| Metabolome | 3 | 2025 | 322 | 1.530 |
Why?
|
| Overweight | 5 | 2022 | 386 | 1.490 |
Why?
|
| Firefighters | 4 | 2016 | 34 | 1.430 |
Why?
|
| Cancer Survivors | 9 | 2025 | 251 | 1.390 |
Why?
|
| Cisplatin | 5 | 2025 | 285 | 1.140 |
Why?
|
| Child | 42 | 2025 | 25847 | 1.130 |
Why?
|
| Neoplasms | 7 | 2025 | 2984 | 1.040 |
Why?
|
| DNA Methylation | 6 | 2020 | 1139 | 1.010 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 57 | 0.940 |
Why?
|
| Child, Preschool | 25 | 2025 | 14865 | 0.940 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 56 | 0.940 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 39 | 0.900 |
Why?
|
| Obesity | 6 | 2020 | 2437 | 0.880 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 124 | 0.880 |
Why?
|
| Proton Therapy | 2 | 2024 | 151 | 0.840 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 146 | 0.790 |
Why?
|
| Survivors | 4 | 2022 | 358 | 0.760 |
Why?
|
| Weight Loss | 3 | 2016 | 516 | 0.760 |
Why?
|
| Male | 41 | 2025 | 65478 | 0.740 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 1837 | 0.730 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 33 | 0.710 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2021 | 4 | 0.700 |
Why?
|
| Adolescent | 23 | 2025 | 20549 | 0.700 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 1405 | 0.670 |
Why?
|
| Down Syndrome | 2 | 2022 | 231 | 0.670 |
Why?
|
| Hypothyroidism | 1 | 2021 | 99 | 0.660 |
Why?
|
| Humans | 57 | 2025 | 133182 | 0.660 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 27 | 0.650 |
Why?
|
| Bone Marrow | 1 | 2021 | 333 | 0.640 |
Why?
|
| Female | 36 | 2025 | 71396 | 0.620 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 188 | 0.620 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 317 | 0.610 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2020 | 2854 | 0.590 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 212 | 0.580 |
Why?
|
| Prognosis | 9 | 2024 | 5032 | 0.580 |
Why?
|
| Neonatal Screening | 1 | 2020 | 193 | 0.570 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 294 | 0.560 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 150 | 0.550 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.540 |
Why?
|
| Weight Gain | 2 | 2019 | 412 | 0.530 |
Why?
|
| Leukemia | 1 | 2020 | 374 | 0.520 |
Why?
|
| Hearing Loss | 3 | 2025 | 214 | 0.500 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 509 | 0.500 |
Why?
|
| Young Adult | 12 | 2025 | 9921 | 0.490 |
Why?
|
| Ear Diseases | 1 | 2015 | 21 | 0.480 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 180 | 0.450 |
Why?
|
| Biomarkers | 2 | 2021 | 3411 | 0.450 |
Why?
|
| DNA | 1 | 2020 | 1675 | 0.430 |
Why?
|
| Mucositis | 2 | 2024 | 19 | 0.420 |
Why?
|
| Infant | 12 | 2025 | 13235 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 3359 | 0.410 |
Why?
|
| Genome, Human | 1 | 2020 | 1338 | 0.400 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 466 | 0.400 |
Why?
|
| Antineoplastic Agents | 6 | 2025 | 1849 | 0.390 |
Why?
|
| Health Status | 1 | 2014 | 414 | 0.370 |
Why?
|
| Fatigue | 3 | 2022 | 199 | 0.370 |
Why?
|
| Retrospective Studies | 9 | 2024 | 17526 | 0.360 |
Why?
|
| Genetic Variation | 3 | 2019 | 1596 | 0.340 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5435 | 0.320 |
Why?
|
| Body Mass Index | 5 | 2020 | 1710 | 0.320 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 991 | 0.310 |
Why?
|
| Hypospadias | 2 | 2020 | 80 | 0.290 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 168 | 0.290 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 72 | 0.290 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 1468 | 0.270 |
Why?
|
| Incidence | 4 | 2022 | 3385 | 0.250 |
Why?
|
| Counseling | 2 | 2021 | 240 | 0.250 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 295 | 0.240 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.230 |
Why?
|
| Adult | 15 | 2025 | 31616 | 0.220 |
Why?
|
| Machine Learning | 2 | 2025 | 345 | 0.220 |
Why?
|
| Cochlea | 1 | 2024 | 90 | 0.220 |
Why?
|
| Creatinine | 2 | 2023 | 416 | 0.220 |
Why?
|
| Drug Monitoring | 1 | 2025 | 185 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 201 | 0.210 |
Why?
|
| Constipation | 1 | 2024 | 128 | 0.210 |
Why?
|
| Genotype | 3 | 2020 | 2719 | 0.210 |
Why?
|
| Risk Factors | 9 | 2022 | 10935 | 0.210 |
Why?
|
| Counselors | 1 | 2023 | 24 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 40 | 0.200 |
Why?
|
| Forecasting | 2 | 2022 | 373 | 0.200 |
Why?
|
| Intelligence | 1 | 2023 | 107 | 0.200 |
Why?
|
| Neutropenia | 1 | 2024 | 205 | 0.200 |
Why?
|
| Cultural Competency | 1 | 2023 | 53 | 0.190 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.190 |
Why?
|
| Asparaginase | 1 | 2022 | 48 | 0.190 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 103 | 0.180 |
Why?
|
| Genetic Counseling | 1 | 2023 | 246 | 0.180 |
Why?
|
| Metabolic Syndrome | 1 | 2025 | 365 | 0.180 |
Why?
|
| Growth Hormone | 1 | 2021 | 150 | 0.180 |
Why?
|
| Protons | 1 | 2021 | 98 | 0.180 |
Why?
|
| Patch Tests | 1 | 2021 | 7 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 144 | 0.170 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 232 | 0.170 |
Why?
|
| Erythema | 1 | 2021 | 29 | 0.170 |
Why?
|
| Executive Function | 1 | 2021 | 125 | 0.170 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.170 |
Why?
|
| Case-Control Studies | 5 | 2023 | 3408 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 5191 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 211 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 195 | 0.160 |
Why?
|
| Biliary Atresia | 1 | 2023 | 206 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 767 | 0.160 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 32 | 0.160 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 44 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 187 | 0.160 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.160 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 253 | 0.150 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 153 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2020 | 144 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 77 | 0.150 |
Why?
|
| Age Factors | 4 | 2024 | 2954 | 0.150 |
Why?
|
| Device Removal | 1 | 2021 | 223 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 118 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 134 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 196 | 0.150 |
Why?
|
| Transportation | 1 | 2018 | 29 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2019 | 241 | 0.150 |
Why?
|
| Sleep | 1 | 2021 | 370 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2022 | 1467 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2020 | 290 | 0.140 |
Why?
|
| SEER Program | 1 | 2019 | 222 | 0.140 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 159 | 0.140 |
Why?
|
| Social Class | 1 | 2019 | 207 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1340 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2019 | 752 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 398 | 0.140 |
Why?
|
| Travel | 1 | 2018 | 125 | 0.140 |
Why?
|
| Adiposity | 2 | 2020 | 207 | 0.140 |
Why?
|
| Middle Aged | 5 | 2021 | 28912 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2019 | 372 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 965 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 97 | 0.130 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 19 | 0.130 |
Why?
|
| Recurrence | 1 | 2020 | 1469 | 0.130 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 454 | 0.130 |
Why?
|
| Neutrophils | 1 | 2019 | 362 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2092 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 493 | 0.130 |
Why?
|
| Computational Biology | 1 | 2021 | 887 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 301 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2018 | 252 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 24 | 0.120 |
Why?
|
| Registries | 1 | 2022 | 1582 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 936 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 411 | 0.110 |
Why?
|
| Prevalence | 2 | 2022 | 2627 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2014 | 94 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1193 | 0.100 |
Why?
|
| Self Report | 1 | 2016 | 552 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1914 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2020 | 6571 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1692 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 860 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 3735 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 549 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 2144 | 0.090 |
Why?
|
| Alleles | 1 | 2015 | 1694 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 448 | 0.080 |
Why?
|
| Pediatrics | 1 | 2019 | 1220 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2019 | 2718 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8627 | 0.080 |
Why?
|
| United States | 4 | 2018 | 11711 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3169 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 347 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2025 | 3715 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 126 | 0.050 |
Why?
|
| Mediator Complex | 1 | 2023 | 61 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2025 | 415 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 42 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 203 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 243 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 244 | 0.040 |
Why?
|
| Homozygote | 1 | 2023 | 561 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 254 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 392 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 58 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 58 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 469 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 1182 | 0.040 |
Why?
|
| Physical Phenomena | 1 | 2018 | 3 | 0.040 |
Why?
|
| Motor Vehicles | 1 | 2018 | 11 | 0.040 |
Why?
|
| Automation | 1 | 2018 | 63 | 0.040 |
Why?
|
| Vehicle Emissions | 1 | 2018 | 20 | 0.040 |
Why?
|
| Exome | 1 | 2023 | 1085 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 3664 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 603 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 612 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 685 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 185 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1307 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1253 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1073 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1608 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2014 | 31 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 712 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2014 | 68 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1363 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1420 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3794 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 361 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2650 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1351 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1861 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1620 | 0.020 |
Why?
|